The bill improves consumer clarity about real eggs and related nutrition/allergy safety and benefits egg producers, but it imposes compliance costs and labeling limits that can reduce choices and raise costs for plant-based makers, retailers, and some consumers.
All consumers — especially low-income families, parents, and people with egg allergies — will get clearer labeling and nutrition guidance that identifies real eggs as an affordable source of protein, iron, B12, vitamin A, and choline and prevents non-egg products from being marketed as eggs.
Producers of real egg products (including small egg farms and packagers) will face less marketplace confusion and may gain improved marketability and clearer product positioning.
Shoppers comparing animal- vs. plant-based products will receive more accurate information about protein quality and digestibility, helping them make better-informed purchasing decisions.
Small food manufacturers and plant-based product producers will face costs for reformulation, relabeling, or removal of nonconforming products, and retailers/distributors may experience inventory disruptions and other compliance expenses.
Consumers — particularly those who prefer plant-based alternatives — may see reduced product choice and potentially higher prices as some alternatives become less available or more expensive due to compliance costs.
The labeling restrictions could bias regulation and market perception toward whole-egg products and against plant-based innovation, potentially chilling competition in alternative-protein markets.
Based on analysis of 4 sections of legislative text.
Prohibits using egg‑related market names on non‑egg foods in interstate commerce, defines eggs/egg products, requires FDA guidance and a two‑year enforcement report.
Prohibits labeling or offering for sale across state lines any food using an egg‑related market name unless the product meets new statutory definitions for “egg” or “egg product.” It defines “egg” as the reproductive output of avian poultry (including albumen or yolk that was encased in a calcium‑based shell) and ties “egg product” and covered market names to existing federal regulations (21 C.F.R. part 160 and related USDA regs). Requires the Department of Health and Human Services, through the FDA Commissioner, to publish draft enforcement guidance within 180 days and final guidance within one year, voids any prior inconsistent FDA guidance, and mandates a report to Congress within two years describing enforcement actions and any remaining mislabeled products along with an updated enforcement plan.
Introduced September 30, 2025 by Elise M. Stefanik · Last progress September 30, 2025